Tech Company Financing Transactions

Cirius Therapeutics Funding Round

Cirius Therapeutics, based in San Diego, received $40 million from Frazier Healthcare Partners, Novo Ventures and private investors.

Transaction Overview

Company Name
Cirius Therapeutics
Announced On
4/11/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors

Frazier Healthcare Partners (Lead Investor) (Dan Estes)

Novo Ventures (Lead Investor) (Nilesh Kumar)

Proceeds Purpose
Cirius will use the proceeds to complete the ongoing EMMINENCE trial, a Phase 2b study of MSDC-0602K, a next-generation insulin sensitizer, for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12651 High Bluff Dr. 150
San Diego, CA 92130
USA
Phone
(616) 450-1613
Website
www.ciriustx.com
Email Address
Not Recorded
Overview
Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial.
Profile
Cirius Therapeutics LinkedIn Company Profile
Social Media
Cirius Therapeutics Company Twitter Account
Company News
Cirius Therapeutics News
Facebook
Cirius Therapeutics on Facebook
YouTube
Cirius Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bob Baltera
  Bob Baltera LinkedIn Profile  Bob Baltera Twitter Account  Bob Baltera News  Bob Baltera on Facebook
Chief Financial Officer
Brian Farmer
  Brian Farmer LinkedIn Profile  Brian Farmer Twitter Account  Brian Farmer News  Brian Farmer on Facebook
Chief Medical Officer
Howard Dittrich
  Howard Dittrich LinkedIn Profile  Howard Dittrich Twitter Account  Howard Dittrich News  Howard Dittrich on Facebook
Chief Scientific Officer
Jerry Colca
  Jerry Colca LinkedIn Profile  Jerry Colca Twitter Account  Jerry Colca News  Jerry Colca on Facebook
VP - Bus. Development
Angeline Shashlo
  Angeline Shashlo LinkedIn Profile  Angeline Shashlo Twitter Account  Angeline Shashlo News  Angeline Shashlo on Facebook
VP - Operations
Julie Iwashita
  Julie Iwashita LinkedIn Profile  Julie Iwashita Twitter Account  Julie Iwashita News  Julie Iwashita on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/11/2017: Evisors venture capital transaction
Next: 4/11/2017: Curacity venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.